mTOR Signaling Pathway in Neurodegeneration

Migration, Crosslink

📖

mTOR Signaling Pathway in Neurodegeneration

active

wiki page Created: 2026-04-02T07:19:52 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-mechanisms-mtor-signaling-neurodege

📖 Wiki Page

mechanism1574 wordssynced 2026-04-02

mTOR Signaling Pathway in Neurodegeneration

Overview

The mammalian target of rapamycin (mTOR) signaling pathway is a central regulator of cell growth, metabolism, protein synthesis, and autophagy. [mTOR](/mechanisms/mtor-signaling-pathway-pathway) integrates signals from nutrients, growth factors, energy status, and stress to coordinate cellular homeostasis. In neurodegenerative diseases, [mTOR](/mechanisms/mtor-signaling-pathway) signaling is frequently dysregulated, contributing to impaired autophagy, abnormal protein aggregation, synaptic dysfunction, and neuronal death. The mTOR pathway represents a promising therapeutic target, with mTOR inhibitors like rapamycin showing neuroprotective effects in preclinical models of Alzheimer's disease (AD), Parkinson's disease (PD), and other neurodegenerative disorders. [@kodali2025]

Key Molecular Players

...

mTOR Signaling Pathway in Neurodegeneration

Overview

The mammalian target of rapamycin (mTOR) signaling pathway is a central regulator of cell growth, metabolism, protein synthesis, and autophagy. [mTOR](/mechanisms/mtor-signaling-pathway-pathway) integrates signals from nutrients, growth factors, energy status, and stress to coordinate cellular homeostasis. In neurodegenerative diseases, [mTOR](/mechanisms/mtor-signaling-pathway) signaling is frequently dysregulated, contributing to impaired autophagy, abnormal protein aggregation, synaptic dysfunction, and neuronal death. The mTOR pathway represents a promising therapeutic target, with mTOR inhibitors like rapamycin showing neuroprotective effects in preclinical models of Alzheimer's disease (AD), Parkinson's disease (PD), and other neurodegenerative disorders. [@kodali2025]

Key Molecular Players

| Component | Function | Disease Relevance | [@abdelaziz2025]
|-----------|----------|-------------------| [@jin2025]
| mTOR | Serine/threonine kinase, catalytic subunit of mTORC1 and mTORC2 | Central regulator, hyperactive in AD/PD | [@tao2024]
| Raptor | Regulatory protein associated with mTORC1 | mTORC1 assembly and substrate recruitment | [@garca2024]
| Rictor | Regulatory protein associated with mTORC2 | mTORC2 assembly and Akt activation | [^6]
| mLST8/GβL | Core subunit of both complexes | Structural stability | [^7]
| TSC1/TSC2 | Tuberous sclerosis complex, GTPase-activating protein | Rheb inhibition, nutrient sensing | [^8]
| Rheb | GTPase, direct activator of mTORC1 | Amino acid and growth factor signaling | [^9]
| S6K1 | p70 ribosomal protein S6 kinase 1 | Protein synthesis, synaptic plasticity | [@he2021]
| 4E-BP1 | eukaryotic translation initiation factor 4E-binding protein 1 | Translation regulation | [^11]
| ULK1 | Unc-51-like autophagy-activating kinase 1 | [Autophagy](/entities/autophagy) initiation | [@jiang2020]
| ATG13 | Autophagy-related protein 13 | Autophagy complex component | [@zhao2021]
| [TFEB](/entities/tfeb) | Transcription factor EB | Lysosomal biogenesis and autophagy | [@wang2019]

Pathway Diagram

Mermaid diagram (expand to render)

mTORC1 vs mTORC2

The mTOR kinase exists in two structurally and functionally distinct complexes: [@sarkar2020]

mTORC1

Composition: mTOR, Raptor, mLST8, PRAS40
Sensors: Nutrients (amino acids), growth factors, energy status, stress
Downstream targets: S6K1, 4E-BP1, ULK1, TFEB
Functions: Protein synthesis, autophagy inhibition, lipid synthesis, metabolism
In disease: Constitutively active, inhibits beneficial autophagy

mTORC2

Composition: mTOR, Rictor, mLST8, Protor1/2
Sensors: Growth factors, cellular integrity
Downstream targets: Akt (Ser473), SGK1, PKCα
Functions: Cell survival, cytoskeleton organization, ion transport
In disease: Often impaired, affects Akt signaling

Disease-Specific Mechanisms

Alzheimer's Disease

In AD, mTOR signaling is consistently hyperactive, contributing to multiple pathological features:

Autophagy Impairment: mTORC1 overactivation inhibits ULK1 complex, blocking autophagosome formation. This impairs clearance of Aβ aggregates and damaged organelles, leading to accumulation of toxic protein aggregates and dysfunctional mitochondria.

Synaptic Dysfunction: Hyperactive mTOR/S6K1 signaling alters synaptic plasticity mechanisms. While acute mTOR activation can enhance LTP, chronic overactivation disrupts translational homeostasis at synapses, leading to synaptic spine loss and memory deficits.

Aβ and Tau Interaction: Aβ oligomers activate PI3K/Akt/mTOR pathway through NMDA receptor manipulation. Tau protein also affects mTOR signaling through multiple mechanisms, creating a vicious cycle of pathology amplification.

Translation Dysregulation: Hyperphosphorylation of 4E-BP1 by mTORC1 disrupts cap-dependent translation, affecting synthesis of synaptic proteins crucial for learning and memory.

Therapeutic Implications: mTOR inhibitors (rapamycin, everolimus) enhance autophagy, reduce Aβ and tau pathology, and improve cognitive function in mouse models. Combination with other approaches may be most effective.

Parkinson's Disease

In PD, mTOR dysregulation contributes to α-synuclein aggregation and dopaminergic neuron vulnerability:

α-Synuclein Clearance: Impaired autophagy due to mTOR overactivation prevents proper clearance of α-synuclein. Rab GTPases involved in autophagosome-lysosome fusion are also affected by mTOR signaling.

Dopaminergic Neuron Sensitivity: Substantia nigra pars compacta neurons have high metabolic demands and are particularly vulnerable to mTOR-related autophagy impairment. Mitochondrial dysfunction in PD further compounds this vulnerability.

LRRK2 Interaction: LRRK2 mutations (G2019S) common in familial PD can affect mTOR signaling. LRRK2 kinase activity influences autophagy regulation through multiple pathways.

Therapeutic Strategies: mTOR inhibitors protect dopaminergic neurons in toxin-based PD models (MPTP, 6-OHDA). Rapamycin and its analogs (rapalogs) are being explored for PD therapy.

Amyotrophic Lateral Sclerosis (ALS)

mTOR signaling is altered in ALS through multiple mechanisms:

FUS and TDP-43 Pathology: Mutations in FUS and TDP-43 affect mTOR localization and signaling. Stress granule formation, common in ALS, interacts with mTOR pathways.

Autophagy Dysfunction: Impaired autophagy contributes to aggregation of mutant SOD1, FUS, and TDP-43 proteins. Motor neurons are particularly sensitive to autophagy impairment.

axonal Transport: mTOR regulates cytoskeletal dynamics and axonal transport. Dysregulation affects delivery of organelles and proteins to neuromuscular junctions.

Therapeutic Potential: mTOR inhibition shows benefit in SOD1 and TDP-43 mouse models. However, timing and duration of treatment are critical considerations.

Huntington's Disease

mTOR hyperactivation contributes to mutant huntingtin (mHtt) pathology:

mHtt Effects: Mutant huntingtin protein activates mTORC1 through multiple mechanisms, including PI3K/Akt pathway stimulation.

Autophagy Inhibition: mTOR overactivity impairs autophagic clearance of mHtt aggregates. Defective autophagy leads to accumulation of toxic protein species.

Translational Dysregulation: Altered mTOR/S6K1 signaling affects translation of synaptic proteins and neurotrophic factors.

Therapeutic Approach: Rapamycin enhances clearance of mHtt and improves phenotype in mouse models. Combination with other autophagy inducers may be beneficial.

Autophagy Regulation by mTOR

The relationship between mTOR and autophagy is central to neurodegeneration:

Mermaid diagram (expand to render)

When mTORC1 is active:

ULK1 is phosphorylated and inhibited
ATG13 is hyperphosphorylated, reducing its affinity for ULK1
Beclin-1 complex formation is suppressed
Autophagosome nucleation is blocked

When mTORC1 is inhibited (e.g., by rapamycin, fasting, or exercise):

ULK1 is activated and initiates autophagy
ATG proteins are recruited to phagophore
Autophagosomes form and fuse with lysosomes
Cellular components are degraded and recycled

Therapeutic Strategies

mTOR Inhibitors

| Drug | Mechanism | Clinical Status | Notes |
|------|-----------|-----------------|-------|
| Rapamycin | Allosteric mTORC1 inhibitor | FDA approved (transplant, oncology) | First-generation, induces feedback loops |
| Everolimus | Rapamycin analog | FDA approved (oncology, transplant) | Similar mechanism to rapamycin |
| Temsirolimus | Rapamycin analog | FDA approved (renal cell carcinoma) | Pro-drug of rapamycin |
| Rapamycin analogs (rapalogs) | mTORC1 inhibition | Various trials | May be safer for chronic use |

ATP-Competitive mTOR Inhibitors

| Drug | Mechanism | Clinical Status | Notes |
|------|-----------|-----------------|-------|
| Torin 1 | mTORC1/2 catalytic inhibitor | Preclinical | Potent, not brain-penetrant |
| AZD8055 | mTORC1/2 inhibitor | Preclinical/Phase 1 | Bioavailable |
| INK128 | mTORC1/2 inhibitor | Phase 1/2 trials | Brain-penetrant |

Combination Approaches

mTOR + Autophagy Induction: mTOR inhibitors combined with other autophagy activators (lithium, carbamazepine, trehalose)

mTOR + Amyloid/Tau Targeting: Combined mTOR inhibition with anti-[Aβ](/proteins/amyloid-beta) or anti-[tau](/proteins/tau) therapies

mTOR + Neurotrophins: Enhancement of BDNF/GDNF signaling alongside autophagy improvement

Intermittent Fasting/Mimetics: Pharmacological mimetics of caloric restriction

Challenges and Considerations

Chronic vs Acute Inhibition: Chronic mTOR suppression may have adverse effects including immunosuppression, metabolic disturbances, and potential impairment of normal neuronal function.

Feedback Loop Activation: Acute mTORC1 inhibition can activate upstream pathways (e.g., insulin/IGF-1 signaling) through feedback loops.

Timing of Intervention: Early intervention may be more effective than treatment after significant neurodegeneration has occurred.

[Blood-Brain Barrier](/entities/blood-brain-barrier): Many mTOR inhibitors have limited brain penetration; development of brain-penetrant analogs is ongoing.

Biomarkers

| Biomarker | What it Measures | Clinical Utility |
|-----------|-----------------|-----------------|
| Phospho-S6K1 (Thr389) | mTORC1 activity | Research use |
| Phospho-4E-BP1 (Ser65) | mTORC1 activity | Research use |
| Phospho-Akt (Ser473) | mTORC2 activity | Research use |
| LC3-II/LC3-I ratio | Autophagy induction | Research use |
| p62/SQSTM1 | Autophagic flux | Research use |

Recent Research Updates (2024-2026)

Recent publications highlighting key advances in this mechanism:

Residual [microglia](/cell-types/microglia-neuroinflammation) following short-term PLX5622 treatment in 5xFAD mice exhibit diminished [NLRP3](/entities/nlrp3-inflammasome) inf... [@kodali2025]
Canagliflozin attenuates neurodegeneration and ameliorates dyskinesia through targeting the NLRP3/Nu... [@abdelaziz2025]
BIN1 deficiency enhances ULK3-dependent autophagic flux and reduces dendritic size in mouse hippocam... [@jin2025]
Oleanonic acid ameliorates mutant Aβ precursor protein-induced oxidative stress, autophagy deficits,... [@tao2024]
A Novel 14mer Peptide Inhibits Autophagic Flux via Selective Activation of the mTORC1 Signalling Pat... [@garca2024]

References

Unknown (n.d.)

[@he2021]: [He[^11]: [Yin et al., TFEB and lysosomal biogenesis (2021)](https://doi.org/10.1016/j.tcb.2021.03.008)
[@jiang2020]: [Jiang et al., ULK1 complex in neurodegeneration (2020)](https://doi.org/10.1016/j.nbd.2020.104912)
[@zhao2021]: [Zhao et al., mTOR and synaptic plasticity (2021)](https://doi.org/10.1002/syn.22198)
[@wang2019]: [Wang et al., mTOR inhibitors in PD models (2019)](https://doi.org/10.1016/j.neuro.2019.05.012)
[@sarkar2020]: [Sarkar et al., Regulation of autophagy by mTOR (2020)](https://doi.org/10.1080/15548627.2020.1725377)

External Links

[mTOR Wikipedia](https://en.wikipedia.org/wiki/MTOR)
[mTOR Signaling in Neurodegeneration - PubMed Review](https://pubmed.ncbi.nlm.nih.gov/)
[ClinicalTrials.gov - mTOR inhibitors in neurodegenerative disease](https://clinicaltrials.gov/)

📖 View canonical wiki page →

Related Entities

mechanisms-mtor-signaling-neurodegeneration

▸Metadataorigin_type: v1_polymorphic_backfill

slug	mechanisms-mtor-signaling-neurodegeneration
kg_node_id	None
entity_type	mechanism
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-ff0e2f962e37
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'mechanisms-mtor-signaling-neurodegeneration'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

2789

Outgoing

2962

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

mTOR Signaling Pathway in Neurodegeneration

mTOR Signaling Pathway in Neurodegeneration

Overview

Key Molecular Players

mTOR Signaling Pathway in Neurodegeneration

Overview

Key Molecular Players

Pathway Diagram

mTORC1 vs mTORC2

mTORC1

mTORC2

Disease-Specific Mechanisms

Alzheimer's Disease

Parkinson's Disease

Amyotrophic Lateral Sclerosis (ALS)

Huntington's Disease

Autophagy Regulation by mTOR

Therapeutic Strategies

mTOR Inhibitors

ATP-Competitive mTOR Inhibitors

Combination Approaches

Challenges and Considerations

Biomarkers

Recent Research Updates (2024-2026)

References

See Also

External Links

💬 Discussion